Naoki Okamura, Astellas CEO (Toru Hanai/Bloomberg via Getty Images)
September 6, 2024 03:45 PM EDT
Pharma
Cell/Gene Tx

Astel­las CEO talks fu­ture be­yond Xtan­di as Japan­ese drug­mak­er puts roots in Boston

Ryan Cross

Senior Science Correspondent

CAM­BRIDGE, MA — When look­ing to the fu­ture of the drug in­dus­try, the al­lure of Boston is strong.

This week, the Japan­ese drug­mak­er Astel­las be­came the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times